# CareCloud, Inc.: Form 10-Q for the period ended Jun 30, 2026

- Company: [CareCloud, Inc.](/companies/ccld.md) (CIK 1582982)
- Form: 10-Q
- Filed: 2026-08-06
- Accepted by EDGAR: Aug 6, 2026, 16:30 ET
- Period: 2026-06-30
- Accession: 0001493152-26-036363
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1582982/000149315226036363/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1582982/000149315226036363/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2026-04-01 to 2026-06-30 | $31.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2026-01-01 to 2026-06-30 | $63.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2026-04-01 to 2026-06-30 | $2.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2026-01-01 to 2026-06-30 | $4.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2026-04-01 to 2026-06-30 | $1.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2026-01-01 to 2026-06-30 | $2.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2026-04-01 to 2026-06-30 | $102.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2026-01-01 to 2026-06-30 | $154.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2026-04-01 to 2026-06-30 | $1.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2026-01-01 to 2026-06-30 | $2.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-04-01 to 2026-06-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2026-01-01 to 2026-06-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-04-01 to 2026-06-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2026-01-01 to 2026-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-04-01 to 2026-06-30 | 42,493,449 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2026-01-01 to 2026-06-30 | 42,482,758 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2026-01-01 to 2026-06-30 | $10.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2026-01-01 to 2026-06-30 | $937.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2026-06-30 | $13.4m | us-gaap:Cash |
| Current assets | at 2026-06-30 | $34.2m | us-gaap:AssetsCurrent |
| Total assets | at 2026-06-30 | $93.8m | us-gaap:Assets |
| Current liabilities | at 2026-06-30 | $33.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2026-06-30 | $76.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2026-06-30 | $17.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 47,175 characters.

The following is a discussion of our condensed consolidated financial condition and results of operations for the three and six months ended June 30, 2026 and 2025, and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Condensed Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “*Forward-Looking Statements”* on page 2 of this Quarterly Report on Form 10-Q.

### Financial Risks

The Company maintains cash balances at Provident Bank (“Provident”) in excess of the FDIC insurance coverage limits. The Company performs periodic evaluations of the relative credit standing of Provident to ensure their credit worthiness. As of June 30, 2026 and December 31, 2025, the Company held cash of approximately $1.3 million and $1.1 million, respectively, in the name of its subsidiaries at banks in Pakistan and Sri Lanka. The banking systems in these countries do not provide deposit insurance coverage. The Company has not experienced any losses on its cash accounts.

### Overview

The Company is a healthcare information technology company that provides technology-enabled revenue cycle management and a full suite of proprietary cloud-based solutions to healthcare providers, from small practices to enterprise medical groups, hospitals, and health systems throughout the United States. Our integrated Software-as-a-Service (“SaaS”) platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health records (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems. The Company also offers printing and mailing and group purchasing services.

Our technology-enabled business solutions can be categorized as follows:

- **Technology-enabled revenue cycle management:**
- Revenue Cycle Management services including end-to-end medical billing, eligibility, analytics, and related services, all of which can be provided utilizing our technology platform and robotic process automation tools or leveraging a third-party system;
- Medical coding and credentialing services to improve provider collections, back-end cost containment, and drive total revenue realization for our healthcare clients; and
- Healthcare claims clearinghouse which enables our clients to electronically scrub and submit claims and process payments from insurance companies.
- **Cloud-based software:**
- Electronic Health Records designed for ambulatory and inpatient care environments, which are user-friendly and integrated with our business services, and enable our healthcare provider clients to enhance patient care delivery, optimize clinical workflows, reduce documentation errors and potentially qualify for government incentives;
- Practice Management software and related capabilities for both ambulatory and inpatient care settings, which support our clients’ day-to-day business operations and financial workflows, including automated insurance eligibility verification, a robust billing and claims rules engine and other automated tools designed to maximize reimbursement;
- Healthline, which is a medical inventory management system built for healthcare settings that enables real-time tracking of supplies, equipment and consumables across multiple locations such as exam rooms, ambulances and storage closets;
- Marketware, which offers a comprehensive physician strategy suite designed to support healthcare organizations in optimizing physician relationship management, streamlining recruitment and onboarding processes, and leveraging performance analytics. The platform consolidates critical data to enhance referral volume, strengthen provider engagement and drive strategic organizational growth;

33

- Wellsoft, a solution for provider workflows in emergency departments and urgent care facilities, has seamless integration into all major hospital IT systems and ancillary departments providing real-time patient tracking and instant lab orders, drug interaction checking and pharmacy review;
- CareVue is an EHR software that enhances clinical workflows for small hospitals and inpatient behavioral health facilities, driving efficiencies across inpatient settings through enhanced charting tools, e-prescribing, medication management and secure clinical communications;
- Artificial intelligence (“AI”):
- CareCloud cirrusAI is designed to serve as a digital healthcare assistant, helping to enhance clinical decision-making, streamline workflows, reduce administrative burdens, optimize revenue management, and promote patient-centered care. The functions include:
- AI-Powered Clinical Decision Support: CareCloud cirrusAI Guide automates clinical data input, and assists clinicians in workflow tasks, providing real-time, evidence-based recommendations and personalized suggestions via Vertex AI’s generative AI tools for providers to consider. This innovation can lead to enhanced diagnosis accuracy and treatment planning.
- AI-Powered Virtual Support Assistant: CareCloud cirrusAI Chat facilitates natural language conversations with practice staff members, offering valuable assistance in navigating CareCloud Electronic Health Records workflows. This tool streamlines post-training and onboarding for new staff, reducing response times and providing real-time assistance, ultimately saving time.
- AI-Driven Appeals: CareCloud cirrusAI Appeals generates customized appeal letters by analyzing patient claim details, the appeal’s reason, and the specific payor involved for healthcare workers to review, edit, and send. This functionality supports CareCloud’s RCM teams in optimizing providers’ RCM and securing proper reimbursement.
- CareCloud cirrusAI integrates with CareCloud’s EHR solutions, talkEHR and CareCloud Charts, making it easily accessible to providers of all sizes.
- CareCloud stratusAI Desk Agent is an agentic AI phone receptionist designed to modernize and automate patient phone interactions. This tool brings conversational AI directly into the call center workflow, eliminating hold times and reducing manual workload while delivering accurate, around-the-clock phone support.
- Patient Experience Management solutions designed to transform interactions between patients and their clinicians, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services, contactless digital check-in solutions, messaging, and online appointment scheduling tools;
- Business Intelligence and healthcare analytics platforms that allow our clients to derive actionable insights from their vast amount of data; and
- Customized applications, interfaces, and a variety of other technology solutions that support our healthcare clients.
- **Digital health:**
- Chronic care management is a program that supports care for patients with chronic conditions by certified care managers that operate under the supervision of the patient’s regular physician;
- Remote patient monitoring enables patient data collected outside the clinical setting through remote devices to be fed into their provider’s EHR to enable proactive patient care; and
- Telemedicine solutions allow healthcare providers to conduct remote patient visits and extend the timely delivery of care to patients unable to travel to a provider’s office.

34

- **Healthcare IT professional services & staffing:**
- Professional services consisting of a broad range of consulting services including full software implementations and activation, revenue cycle optimization, data analytic services, and educational training services;
- Strategic advisory services to manage system evaluations and selection, provide interim management, and operational assessments;
- Workforce augmentation and on-demand staffing to support our clients as they expand their businesses, seek highly trained personnel, or struggle to address staffing shortages; and
- Managed services includes inpatient and outpatient IT services, government consulting and product development services.

|  |  |
| --- | --- |
| ● | **Empower:** |
|  | Services include: |
|  | ○ Revenue Integrity — risk adjustment, HCC coding and audits and revenue cycle compliance; |
|  | ○ Mergers & Acquisitions — compliance due diligence and integration support for healthcare transactions |
|  | ○ Privacy & Security — HIPAA and HITECH policy development, security risk analysis, and breach response; and |
|  | ○ Compliance & Ethics — compliance program effectiveness audits, ethics program development, OSHA workplace safety programs, and ongoing co-sourced compliance officer support. |

- **MAP App:**
- MAP App is an industry-leading tool for benchmarking and measuring revenue cycle management performance, which was developed by the Healthcare Financial Management Association and is used by top hospitals and healthcare organizations nationwide.

Our medical practice management solutions include:

- **Medical practice management:**
- Medical practice management services are provided to medical practices. In this service model, we provide the medical practice with appropriate facilities, equipment, supplies, support services, nurses and administrative support staff. We also provide management, bill-paying and financial advisory services.

We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of approximately 250 experienced health industry experts throughout the United States. These experts are supported by our highly educated and specialized offshore workforce of approximately 3,100 team members that are approximately 17% of the cost of comparably educated and skilled workers in the U.S. Our unique business model also allowed us to become a leading consolidator in our industry sector, gaining us a reputation for acquiring and positively transforming distressed competitors into profitable operations of CareCloud.

Our offshore operations in the Pakistan Offices and Sri Lanka together accounted for approximately 17% and 18% of total expenses for the six months ended June 30, 2026 and 2025, respectively. A significant portion of those foreign expenses were personnel-related costs (approximately 73% and 77% for the six months ended June 30, 2026 and 2025, respectively). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. We are able to achieve significant cost reductions and leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., the Pakistan Offices and Sri Lanka. Our offshore operations are subject to geopolitical, economic and operational risks; see “Risk Factors” in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K.

### Key Performance Measures

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

Adjusted EBITDA excludes the following elements which are included in GAAP net income:

- Income tax provision or the cash requirements to pay our taxes;
- Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt;
- Foreign currency losses and other non-operating expenditures;
- Stock-based compensation expense which includes cash-settled awards and the related taxes;
- Depreciation and amortization charges;
- Change in contingent consideration;
- Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements; and
- Restructuring costs.

Set forth below is a presentation of our adjusted EBITDA for the three and six months ended June 30, 2026 and 2025:

*($ in thousands)*

|  | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | $31,880 | $27,377 | $63,150 | $55,009 |
| GAAP net income | 1,122 | 2,902 | 2,044 | 4,850 |
| Provision for income taxes | 102 | 42 | 154 | 83 |
| Net interest expense | 742 | 17 | 790 | 33 |
| Foreign exchange loss / other expense | 54 | 41 | 86 | 60 |
| Stock-based compensation expense | 64 | 111 | 128 | 219 |
| Depreciation and amortization | 3,731 | 3,382 | 7,768 | 6,719 |
| Change in contingent consideration | (34) | - | 23 | - |
| Transaction and integration costs | 166 | 11 | 324 | 23 |
| Restructuring costs | - | 23 | - | 137 |
| Adjusted EBITDA | **$5,947** | **$6,529** | **$11,317** | **$12,124** |

Adjusted operating income and adjusted operating margin exclude the following elements that are included in GAAP operating income:

- Stock-based compensation expense which includes cash-settled awards and the related taxes;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
- Change in contingent consideration; and
- Restructuring costs.

36

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue for the three and six months ended June 30, 2026 and 2025:

*($ in thousands)*

|  | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | $31,880 | $27,377 | $63,150 | $55,009 |
| GAAP net income | 1,122 | 2,902 | 2,044 | 4,850 |
| Provision for income taxes | 102 | 42 | 154 | 83 |
| Net interest expense | 742 | 17 | 790 | 33 |
| Other (income) expense - net | (104) | 35 | (126) | 49 |
| GAAP operating income | 1,862 | 2,996 | 2,862 | 5,015 |
| GAAP operating margin | 5.8% | 10.9% | 4.5% | 9.1% |
| Stock-based compensation expense | 64 | 111 | 128 | 219 |
| Amortization of purchased intangible assets | 945 | 193 | 1,873 | 282 |
| Transaction and integration costs | 166 | 11 | 324 | 23 |
| Change in contingent consideration | (34) | - | 23 | - |
| Restructuring costs | - | 23 | - | 137 |
| Non-GAAP adjusted operating income | **$3,003** | **$3,334** | **$5,210** | **$5,676** |
| Non-GAAP adjusted operating margin | 9.4% | 12.2% | 8.3% | 10.3% |

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income:

- Foreign currency losses and other non-operating expenditures;
- Stock-based compensation expense which includes cash-settled awards and the related taxes;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
- Change in contingent consideration;
- Restructuring costs; and
- Income tax expense resulting from the amortization of goodwill related to our acquisitions.

37

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net income to non-GAAP adjusted net income for the three and six months ended June 30, 2026 and 2025:

*($ in thousands)*

|  | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
| --- | ---: | ---: | ---: | ---: |
| GAAP net income | $1,122 | $2,902 | $2,044 | $4,850 |
| Foreign exchange loss / other expense | 54 | 41 | 86 | 60 |
| Stock-based compensation expense | 64 | 111 | 128 | 219 |
| Amortization of purchased intangible assets | 945 | 193 | 1,873 | 282 |
| Transaction and integration costs | 166 | 11 | 324 | 23 |
| Change in contingent consideration | (34) | - | 23 | - |
| Restructuring costs | - | 23 | - | 137 |
| Income tax expense related to goodwill | 50 | - | 50 | - |
| Non-GAAP adjusted net income | **$2,367** | **$3,281** | **$4,528** | **$5,571** |

Set forth below is a reconciliation of our GAAP net income attributable to common shareholders, per share to our non-GAAP adjusted net income per share:

|  | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
| --- | ---: | ---: | ---: | ---: |
| GAAP net income (loss) attributable to common shareholders, per share | $0.00 | $0.04 | $(0.01) | $0.02 |
| Impact of preferred stock dividend | 0.03 | 0.03 | 0.06 | 0.09 |
| Net income per end-of-period share | 0.03 | 0.07 | 0.05 | 0.11 |
| Foreign exchange loss / other expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation expense | 0.01 | 0.00 | 0.01 | 0.01 |
| Amortization of purchased intangible assets | 0.02 | 0.00 | 0.04 | 0.01 |
| Transaction and integration costs | 0.00 | 0.00 | 0.01 | 0.00 |
| Change in contingent consideration | 0.00 | 0.00 | 0.00 | - |
| Restructuring costs | - | 0.00 | - | 0.00 |
| Income tax expense related to goodwill | 0.00 | - | 0.00 | - |
| Non-GAAP adjusted earnings per share | **$0.06** | **$0.07** | **$0.11** | **$0.13** |
| End-of-period common shares | 42,493,859 | 42,322,039 | 42,493,859 | 42,322,039 |

For purposes of determining non-GAAP adjusted earnings per share, the Company used the number of common shares outstanding at the end of June 30, 2026 and 2025. Non-GAAP adjusted earnings per share does not take into account dividends declared or earned on preferred stock.

### Key Metrics

In addition to the line items in our condensed consolidated financial statements, we regularly review the following metrics. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

*Providers and Practices Served:* As of June 30, 2026 and 2025, we provided services to approximately 44,000 and 40,000 providers, respectively (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 2,900 independent medical practices, hospitals and service organizations. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

### Sources of Revenue

*Revenue:* We primarily derive our revenue from subscription-based technology-enabled business solutions, reported in our Healthcare IT segment, which are typically billed as a percentage of payments collected by our customers. This fee includes technology-enabled RCM, as well as the ability to use our EHR, practice management system and other software as part of the bundled fee. These solutions accounted for approximately 75% and 69% of revenue for the three months ended June 30, 2026 and 2025, respectively, and 74% and 67% of revenue for the six months ended June 30, 2026 and 2025, respectively. Other healthcare IT services, including printing and mailing operations, group purchasing and professional services, represented approximately 13% and 19% of revenue for the three months ended June 30, 2026 and 2025, respectively, and 14% and 22% of revenue for the six months ended June 30, 2026 and 2025, respectively.

We earned approximately 12% of our revenue from medical practice management services during both the three and six months ended June 30, 2026 and 2025, respectively. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Medical Practice Management segment.

### Operating Expenses

*Direct Operating Costs.* Direct operating costs consist primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the condensed consolidated statements of operations.

*Selling and Marketing Expense.* Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses.

*General and Administrative Expense.* General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs, insurance, software license fees and outside professional fees.

*Research and Development Expense.* Research and development expense consists primarily of personnel-related costs, software expense and third-party contractor costs.

*Change in contingent consideration.* Contingent consideration represents the portion of consideration payable to the seller of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

*Depreciation and Amortization Expense.* Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to five years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our medical practice management clients is amortized on a straight-line basis over a period of twelve years.

*Restructuring Costs.* Restructuring costs primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements.

*Interest and Other Income (Expense) - net.* Interest income represents interest earned on temporary cash investments and late fees from customers. Interest expense consists primarily of interest costs related to our line of credit, term loans and the amortization of deferred financing costs. Other income (expense) - net results primarily from foreign currency transaction gains/(losses).

*Income Taxes.* In preparing our condensed consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company has returned to profitability, it incurred losses historically and there is uncertainty regarding sufficient future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of June 30, 2026 and December 31, 2025.

### Critical Accounting Policies and Estimates

The critical accounting policies and estimates used in the preparation of our condensed consolidated financial statements that we believe affect our more significant judgments and estimates used in the preparation of our condensed consolidated financial statements presented in this Report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2025.

*Capitalized Software Costs:*

As of June 30, 2026 and December 31, 2025, the carrying amount of internally-developed capitalized software in use was $2.5 million and $5.3 million, respectively. The decrease was due to the amortization exceeding the amounts being capitalized.

There have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026.

### Results of Operations

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown:

|  | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating expenses: |  |  |  |  |
| Direct operating costs | 54.7% | 52.9% | 54.3% | 54.4% |
| Selling and marketing | 4.1% | 4.1% | 4.3% | 4.1% |
| General and administrative | 16.8% | 15.9% | 17.2% | 15.8% |
| Research and development | 6.9% | 3.7% | 7.3% | 4.1% |
| Change in contingent consideration | 0.0% | - | 0.0% | - |
| Depreciation and amortization | 11.7% | 12.4% | 12.3% | 12.2% |
| Restructuring costs | - | 0.1% | - | 0.3% |
| Total operating expenses | 94.2% | 89.1% | 95.4% | 90.9% |
| Operating income | 5.8% | 10.9% | 4.6% | 9.1% |
| Net interest expense | (2.3%) | (0.1%) | (1.3%) | 0.0% |
| Other income (expense) - net | 0.3% | (0.1%) | 0.2% | (0.1%) |
| Income before provision for income taxes | 3.8% | 10.7% | 3.5% | 9.0% |
| Income tax provision | 0.3% | 0.1% | 0.2% | 0.2% |
| Net income | 3.5% | 10.6% | 3.3% | 8.8% |

40

### Comparison of the three and six months ended June 30, 2026 and 2025:

*($ in thousands)*

|  | Three Months Ended June 30, 2026 | 2025 | Change Amount | Percent | Six Months Ended June 30, 2026 | 2025 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net revenue | $31,880 | $27,377 | $4,503 | 16% | $63,150 | $55,009 | $8,141 | 15% |

*Net Revenue.* Net revenue of $31.9 million and $63.2 million for the three and six months ended June 30, 2026, increased by $4.5 million or 16% and increased by $8.1 million or 15% from net revenue of $27.4 million and $55.0 million for the three and six months ended June 30, 2025, respectively. Revenue for the three and six months ended June 30, 2026 includes $24.0 million and $47.0 million relating to technology-enabled business solutions, $3.2 million and $6.3 million related to professional services and $3.7 million and $7.5 million for medical practice management services, respectively. Printing and mailing services and group purchasing services revenue was $1.0 million and $2.3 million for the three and six months ended June 30, 2026, respectively.

During the three and six months ended June 30, 2026, there was approximately $6.8 million and $13.6 million of revenue related to the Medsphere acquisition. The medSR revenue, which is project based, decreased approximately $1.3 million and $4.2 million compared to the three and six months ended June 30, 2025.

*($ in thousands)*

|  | Three Months Ended June 30, 2026 | 2025 | Change Amount | Percent | Six Months Ended June 30, 2026 | 2025 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Direct operating costs | $17,457 | $14,480 | $2,977 | 21% | $34,307 | $29,944 | $4,363 | 15% |
| Selling and marketing | 1,300 | 1,118 | 182 | 16% | 2,714 | 2,249 | 465 | 21% |
| General and administrative | 5,370 | 4,358 | 1,012 | 23% | 10,866 | 8,690 | 2,176 | 25% |
| Research and development | 2,194 | 1,020 | 1,174 | 115% | 4,610 | 2,255 | 2,355 | 104% |
| Change in contingent consideration | (34) | - | (34) | (100%) | 23 | - | 23 | 100% |
| Depreciation | 748 | 594 | 154 | 26% | 1,488 | 1,155 | 333 | 29% |
| Amortization | 2,983 | 2,788 | 195 | 7% | 6,280 | 5,564 | 716 | 13% |
| Restructuring costs | - | 23 | (23) | (100%) | - | 137 | (137) | (100%) |
| Total operating expenses | $30,018 | $24,381 | $5,637 | 23% | $60,288 | $49,994 | $10,294 | 21% |

*Direct Operating Costs.* Direct operating costs of $17.5 million and $34.3 million for the three and six months ended June 30, 2026 increased by $3.0 million or 21% and increased by $4.4 million or 15% compared to direct operating costs of $14.5 million and $29.9 million for the three and six months ended June 30, 2025, respectively. During the three and six months ended June 30, 2026, salary costs increased by $889,000 and $769,000, outsourcing and processing costs increased by $1.9 million and $3.4 million and billable expenses decreased by $46,000 and $381,000, respectively.

*Selling and Marketing Expense.* Selling and marketing expense of $1.3 million and $2.7 million for the three and six months ended June 30, 2026 increased by $182,000 or 16% and $465,000 or 21% from selling and marketing expense of $1.1 million and $2.2 million for the three and six months ended June 30, 2025, respectively. The increase for the three and six months ended June 30, 2026 was primarily due to additional headcount.

*General and Administrative Expense.* General and administrative expense of $5.4 million and $10.9 million for the three and six months ended June 30, 2026 increased by $1.0 million or 23% and $2.2 million or 25% compared to general and administrative expense of $4.4 million and $8.7 million for the three and six months ended June 30, 2025, respectively. During the three and six months ended June 30, 2026, salary costs increased by $530,000 and $890,000, and insurance costs increased by $64,000 and $101,000, respectively. The costs for the newly purchased aircraft used to support business development and maintain client relationships were $276,000 and $438,000 for the three and six months ended June 30, 2026, respectively.

*Research and Development Expense.* Research and development expense of $2.2 million and $4.6 million for the three and six months ended June 30, 2026 increased by approximately $1.2 million or 115% and $2.4 million or 104% from research and development expense of $1.0 million and $2.3 million for the three and six months ended June 30, 2025, respectively. During the six months ended June 30, 2026 and 2025 the Company capitalized approximately $1.6 million and $1.7 million, respectively, of development costs in connection with its internal-use software. The increase in expense was primarily due to a shift in the nature of development activities, with fewer costs qualifying for capitalization as internal-use software, resulting in a greater portion of costs being recognized as operating expenses in the current period.

*Change in Contingent Consideration.* Change in contingent consideration of $(34,000) and $23,000 for the three and six months ended June 30, 2026 relates to adjustments for probable future payments required under the purchase agreement for certain acquisitions.

*Depreciation Expense.* Depreciation expense of $748,000 and $1.5 million for the three and six months ended June 30, 2026 increased by $154,000 and $333,000 from depreciation of $594,000 and $1.2 million for the three and six months ended June 30, 2025, respectively.

*Amortization Expense.* Amortization expense of $3.0 million and $6.3 million for the three and six months ended June 30, 2026 increased by $195,000 or 7% and $716,000 or 13% from amortization expense of $2.8 million and $5.6 million for the three and six months ended June 30, 2025, respectively. The increase in the expense is due to the amortization of the intangible assets acquired in the recent acquisitions.

*Restructuring Costs.* There were no restructuring costs for the three and six months ended June 30, 2026 as compared to $23,000 and $137,000 for the three and six months ended June 30, 2025, respectively, which primarily consists of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements.

*($ in thousands)*

|  | Three Months Ended June 30, 2026 | 2025 | Change Amount | Percent | Six Months Ended June 30, 2026 | 2025 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest income | $73 | $51 | $22 | 43% | $83 | $93 | $(10) | (11%) |
| Interest expense | (815) | (68) | 747 | 1,099% | (873) | (126) | 747 | 593% |
| Other income (expense) - net | 104 | (35) | 139 | 397% | 126 | (49) | 175 | 357% |
| Income tax provision | 102 | 42 | 60 | 143% | 154 | 83 | 71 | 86% |

*Interest Income.* Interest income of $73,000 and $83,000 for the three and six months ended June 30, 2026 increased by $22,000 and decreased by $10,000 from interest income of $51,000 and $93,000 for the three and six months ended June 30, 2025, respectively. The interest income represents late fees from customers and interest earned on temporary cash investments.

*Interest Expense.* Interest expense of $815,000 and $873,000 for the three and six months ended June 30, 2026, respectively, increased by $747,000 for both the three and six months periods from interest expense of $68,000 and $126,000, respectively, in 2025. The interest expense increase was due to the borrowings under the term loan and the line of credit during 2026. Interest expense on the term loan was $621,000 for both the three and six months ended June 30, 2026, and includes fees related to the term loan. Interest expense on the line of credit was $121,000 for both the three and six months ended June 30, 2026, and includes fees related to the line of credit.

*Other Income (Expense)–net.* Other income – net was $104,000 and $126,000 for the three and six months ended June 30, 2026 compared to other expense – net of $35,000 and $49,000 for the three and six months ended June 30, 2025, respectively. Other expense or income primarily represents foreign currency transaction gains or losses. These transaction gains or losses result from revaluing intercompany accounts which are denominated in U.S. dollars that represent amounts payable/receivable between the entities. Whenever the exchange rate varies, the gains or losses are recorded in the condensed consolidated statements of operations.

*Income Tax Provision.* The provision for income taxes was $102,000 and $154,000 for the three and six months ended June 30, 2026, respectively, compared to $42,000 and $83,000 for the three and six months ended June 30, 2025, respectively. The increase was primarily due to a $50,000 deferred income tax provision for the three and six months ended June 30, 2026 related to the amortization of goodwill for tax purposes. There was no deferred tax liability recorded at December 31, 2025. There were no deferred income taxes for the three months and six months ended June 30, 2025.

The current income tax expense for the three and six months ended June 30, 2026 was approximately $52,000 and $102,000, respectively, which represents state minimum taxes and foreign income taxes. Although the Company has returned to profitability, it incurred losses historically and there is uncertainty regarding sufficient future U.S. taxable income, which makes realization of deferred tax losses difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at June 30, 2026 and December 31, 2025.

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, extending key provisions of the 2017 Tax Cuts and Jobs Act including, but not limited to, federal bonus depreciation and deductions for domestic research and development expenditures. OBBBA did not have a material impact on the Company’s condensed consolidated financial statements.

### Liquidity and Capital Resources

During April 2026, the Company terminated the credit line with Provident and entered into a $50 million joint credit facility with Citizens Bank, N.A. and Provident consisting of a four-year $40 million term loan and a $10 million revolving line of credit. As of June 30, 2026, there were $9.0 million outstanding on the line of credit and $39.2 million outstanding on the term loan. The Company fully redeemed the outstanding Series B Preferred Stock in May 2026. Approximately $41.6 million of the new credit facility was used for the redemption. As of June 30, 2025, there were no borrowings under the Provident credit facility.

As of June 30, 2026, the Company had total cash of $13.4 million and net working capital of $695,000. For the six months ended June 30, 2026, cash provided by operations was $10.7 million and cash provided by financing activities was $2.3 million, offset by cash used in investing activities of $3.2 million, resulting in an increase in cash of $9.8 million after accounting for the effect of $8,000 of exchange rate changes.

For the six months ended June 30, 2026, the Company recorded net income of $2.0 million. Management continues to focus on the Company’s overall profitability, including managing expenses, and to the extent possible growing revenue, and expects that these efforts will continue to enhance our liquidity and financial position. Our expectations regarding future financial performance, including revenue, adjusted EBITDA and earnings-per-share, are based on management’s current beliefs and assumptions regarding, among other things, the signing and continuation of certain client and vendor relationships, the anticipated timing and scope of client projects, and our timely execution of integration and expense-management initiatives intended to align our cost structure with those objectives. If these assumptions prove incorrect or these initiatives are delayed or not fully realized, our results may differ materially. Based on management’s forecasts, the Company will have sufficient liquidity to meet its obligations as they become due for the next twelve months from the date of the financial statements’ issuance.

We have not been adversely affected by inflation as typically we receive a percentage of the fees our clients collect from our revenue cycle management services. Additionally, our medical practice management contracts are based on our costs plus a percentage of the medical practice’s operating income. We continue to monitor the impact of inflation in order to minimize its effects through pricing strategies, productivity improvements and cost reductions. In the event of inflation, we believe that we will be able to pass on any price increases for fixed rate contracts to our customers, as the prices that we charge are not governed by long-term contracts. The interest rate on the Citizens’ term loan and the line of credit is based on the secured overnight financing rate which has slightly declined since inception.

The following table summarizes our cash flows for the periods presented:

*($ in thousands)*

|  | Three Months Ended June 30, 2026 | 2025 | Six Months Ended June 30, 2026 | 2025 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net cash provided by operating activities | $7,073 | $7,408 | $10,684 | $12,521 | $(2,098) | (17%) |
| Net cash used in investing activities | (2,006) | (1,993) | (3,238) | (3,503) | 265 | 8% |
| Net cash provided by (used in) financing activities | 4,474 | (1,762) | 2,324 | (3,694) | 6,279 | 170% |
| Effect of exchange rate changes on cash and restricted cash | - | (18) | 8 | (29) | 37 | 128% |
| Net increase in cash and restricted cash | $9,541 | $3,635 | $9,778 | $5,295 | $4,483 | 85% |

The income before income taxes was $1.2 million and $2.2 million for the three and six months ended June 30, 2026, respectively, which included $3.7 million and $7.8 million of non-cash depreciation and amortization, respectively. The income before income taxes was $2.9 million and $4.9 million for the three and six months ended June 30, 2025, respectively, which included $3.4 million and $6.7 million of non-cash depreciation and amortization, respectively.

### Operating Activities

Net cash provided by operating activities was $10.7 million and $12.5 million during the six months ended June 30, 2026 and 2025, respectively. There was a decrease in net income of $2.8 million together with the following changes in non-cash items: an increase in depreciation and amortization of $1.0 million and a decrease in stock-based compensation of $91,000. Accounts receivable decreased $827,000 and increased $958,000 for the six months ended June 30, 2026 and 2025, respectively. Accounts payable and other liabilities decreased by $2.1 million and increased $377,000 during the six months ended June 30, 2026 and 2025, respectively. Other assets decreased by $73,000 and increased by $838,000 during the six months ended June 30, 2026 and 2025, respectively.

### Investing Activities

Net cash used in investing activities was $3.2 million and $3.5 million for the six months ended June 30, 2026 and 2025, respectively. Capital expenditures were $937,000 and $1.8 million for the six months ended June 30, 2026 and 2025, respectively. The capital expenditures for the six months ended June 30, 2026 and 2025 primarily represented computer equipment purchased and leasehold improvements for the Pakistan Offices. Software development costs of $1.6 million and $1.7 million for the six months ended June 30, 2026 and 2025, respectively, were capitalized in connection with the development of software for providing technology-enabled business solutions. Payment for acquisitions was $681,000 and $40,000 for the six months ended June 30, 2026 and 2025, respectively.

### Financing Activities

Net cash provided by financing activities was $2.3 million during the six months ended June 30, 2026 compared to net cash used in financing activities of $3.7 million during the six months ended June 30, 2025. Cash provided by financing activities during the six months ended June 30, 2026 included $39.7 million of net proceeds from the term loan, $9 million of borrowings on the line of credit, offset by $6.4 million of preferred stock dividends, $1.2 million of repayments for debt obligations and $618,000 for payment of contingent consideration. Approximately $38.2 million was used for the redemption of the Series B Preferred stock. Cash used in financing activities during the six months ended June 30, 2025 included $3.3 million of preferred stock dividends, $355,000 of repayments for debt obligations and $22,000 of tax withholding obligations paid in connection with stock awards issued to employees.

### Contractual Obligations and Commitments

We had contractual obligations under our Provident line of credit and have contractual obligations under the new credit facility obtained in April 2026. We were in compliance with all covenants as of June 30, 2026. We also maintain operating leases for property and certain office equipment. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026.

### Off-Balance Sheet Arrangements

As of June 30, 2026, and 2025, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

### Cybersecurity Incident

On March 16, 2026, the Company detected a security incident in its CareCloud Health division that affected the functionality and data access to one of its six electronic health record environments for approximately eight hours until the Company fully restored all functionality and data access during that evening. The forensic investigation determined that an unauthorized third party gained access to one cloud account supporting the previously identified electronic health record environment and found no evidence that any other Company platforms, divisions, systems, data or environments were affected. The investigation found no evidence of unauthorized activity related to the incident after March 16, 2026 and all affected systems remain fully operational. Subject to applicable policy terms, limits, retentions, exclusions and coverage determinations, the Company currently believes its available cybersecurity insurance coverage is likely to be sufficient for the losses it currently anticipates in connection with the incident. See Note 9, Commitments and Contingencies, of the Notes to Condensed Consolidated Financial Statements for additional information regarding the incident, including related legal proceedings.

## Market risk

As filed, 1,386 characters.

On December 11, 2023, the Board of Directors suspended the monthly cash dividends for Series A Preferred Stock and Series B Preferred Stock beginning with the payment scheduled for December 15, 2023 together with the outstanding dividends that were declared. During this suspension, dividends continued to accumulate in arrears on the remaining Series A and Series B Preferred Stock. Effective in September 2024, there was a change in the dividend rate on the Series A Preferred Stock from 11.00% to 8.75%. Due to the conversion of the majority of the Series A Preferred Stock in March 2025, the dividend amount due on the converted shares resulting from the suspension was settled. During February 2025 and continuing monthly thereafter, the Company resumed payment of the dividends, paying one month of dividends in arrears each month based on the oldest dividend amount outstanding. Beginning in February 2026, the Company began making one additional dividend payment each month on the Series B Preferred Stock to begin to satisfy the dividend arrearage. Due to the redemption of all of the Series B Preferred Stock in May 2026, the dividend amount due on the redeemed Series B Preferred Stock shares resulting from the suspension was settled. The Company has approximately $2.7 million of dividends declared and accumulated on the Series A Preferred Stock due as of the filing date.

## Controls and procedures

As filed, 2,477 characters.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, based on the Internal Control-Integrated Framework (2013 framework) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2026 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, as of June 30, 2026, our Chief Executive Officer and Interim Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective. We will continue to improve the controls to ensure that information required to be disclosed by the Company in reports that it files under the Exchange Act is reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

#### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and l5d-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 6,194 characters.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I—Item 1A. “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 12, 2026, which could materially affect our business, financial condition and/or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and/or future results.

*The recent cybersecurity incident in our CareCloud Health division could result in material costs, regulatory action and reputational harm.*

We experienced a cybersecurity incident involving unauthorized third party access to one cloud account supporting one of our CareCloud Health division electronic health record environments. The forensic investigation determined that an unauthorized third party claimed to have exfiltrated personally identifiable information and protected health information. While we have taken steps to contain and remediate the incident, including engaging third-party cybersecurity experts, notifying the affected healthcare customers, potentially affected individuals, and regulatory agencies, there can be no assurance that additional vulnerabilities will not be identified or that further unauthorized activity will not occur. The incident has resulted in, and may continue to result in, costs related to investigation, remediation, customer and patient notification, and legal proceedings. Additionally, this incident may harm our reputation, result in customer attrition, and expose us to regulatory penalties. We have provided notifications to applicable federal and state regulatory agencies as required. Regulatory agencies, including the U.S. Department of Health and Human Services Office for Civil Rights and state attorneys general, may open inquiries or investigations into the incident, which could result in fines, penalties, corrective action plans or other remedies, and responding to any such inquiries could involve costs and management attention. We may also face contractual claims from healthcare-provider customers, including indemnification claims or claims under business associate agreements. The incident may result in increased insurance premiums or retentions, or reduced availability of cybersecurity insurance on acceptable terms, and we expect to continue to incur costs to further enhance our information security safeguards. If our remediation efforts are not successful or timely, or if additional vulnerabilities are exploited, our business, financial condition, and results of operations could be materially adversely affected.

*The use of artificial intelligence by threat actors, and our own development and deployment of AI-enabled products, may increase the risk and potential severity of future cybersecurity incidents.*

Advances in AI have lowered the barriers to, and increased the sophistication of, cyberattacks, including AI-generated phishing and social-engineering campaigns, deepfake-enabled impersonation, and automated discovery and exploitation of vulnerabilities, and we expect the frequency and sophistication of such attacks to increase. In addition, our own AI solutions, including CareCloud cirrusAI and CareCloud stratusAI, process personally identifiable information and protected health information and rely on third-party models and cloud infrastructure, which may create new attack surfaces and data-handling risks. Although we have implemented and continue to enhance safeguards, we cannot guarantee these measures will prevent future incidents, and any future incident could result in costs, regulatory action, litigation, customer attrition and reputational harm materially greater than those associated with the March 2026 incident.

*Geopolitical or economic developments affecting our offshore operations could increase our costs and impair our ability to service client accounts.*

As described in our Annual Report on Form 10-K, our business model depends on our offshore operations in Pakistan, Azad Jammu and Kashmir and Sri Lanka, where approximately 3,100 of our team members are located and where personnel costs are significantly lower than in the United States. Regional conflicts or the escalation of tensions in or affecting the regions where we operate, trade restrictions, sanctions, changes in diplomatic relations or political stability, currency devaluation or restrictions on the repatriation of funds, infrastructure disruptions, visa or travel restrictions, and local wage inflation could increase our operating costs or impair our ability to deliver services to our clients at current service levels and prices. Because our offshore operations are concentrated in a small number of locations, a disruption affecting any one of them could have a disproportionate impact on our ability to deliver services. If we were required to shift a material portion of this work to the United States or other higher-cost locations, our expenses would increase materially, our margins would decline, and we may be unable to serve client accounts at current service levels or competitive prices.

*We maintain our cash at financial institutions, often in balances that exceed federally insured limits.*

The financial markets have from time to time encountered volatility associated with concerns about the balance sheets of banks, especially small and regional banks who may have significant losses associated with investments that make it difficult to fund demands to withdraw deposits and other liquidity needs. Although the federal government has announced measures to assist these banks and protect depositors, some banks have already been impacted and others may be materially and adversely impacted. Our business is dependent on bank relationships and we are proactively monitoring the financial health of such bank relationships. Continued strain on the banking system may adversely impact our business, financial condition and results of operations.

Filed Aug 6, 2026.
Source: SEC EDGAR, the filing index for accession 0001493152-26-036363. Last ingested by Listed: Nov 5, 2026, 18:58 ET. No prices; not investment advice.
